Case study: persistent keratitis OS presents in 68-year-old woman

Publication
Article
Optometry Times JournalDigital edition: January 2022
Volume 14
Issue 01

A 68-year-old White woman was referred for persistent keratitis OS and failure on multiple medications. Find out her official diagnosis and treatment plan.

Figure 1. Infectious keratitis before application of Prokera Slim.

Figure 1. Infectious keratitis before application of Prokera Slim.



Presentation

A 68-year-old White woman was referred for persistent keratitis OS and failure on multiple medications: Restasis, Xiidra, prednisolone 1%, Lotemax 0.5%, and Cequa. She was using Systane preservative-free drops, 4 to 6 times daily. Sodium fluorescein staining revealed marked keratitis OS (Figure 1).

Greg Caldwell

Caldwell

Treatment

I educated the patient about her condition, and after lengthy discussion it was decided that a Prokera Slim amniotic membrane would be used to treat the OS.

Follow-up

I instructed my patient to make an appointment to have the Prokera ring removed when her vision cleared (due to membrane dissolving). Her vision cleared 6 days after Prokera Slim insertion. At this point, she was only using Systane preservative-free artificial tears. The ring was removed, and the patient was placed on autologous serum eye drops 20%, 1 drop 6 times per day.

Figure 2. The eye 6 days after application of Prokera Slim. (All figures courtesy of Greg Caldwell, OD, FAAO)

Figure 2. The eye 6 days after application of Prokera Slim. (All figures courtesy of Greg Caldwell, OD, FAAO)


Outcome and observations

The patient presented with a chronic and persistent keratitis OS. The cause was multifactorial with 1 component being toxic keratitis from the various pharmaceuticals used. This patient needed a therapy that supported wound healing and not wound covering. A Prokera Slim was used to provide wound healing. The patient reported no problems or discomfort with Prokera Slim during the 6-day treatment (Figure 2).

The patient responded wonderfully to the therapy and reported increased comfort and improved vision.

READ Dr.Caldwell's full article: Cryopreserved amniotic membrane excels at healing ocular surface wounds

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.